company background image
I9SA logo

Verona Pharma DB:I9SA Stock Report

Last Price

€36.40

Market Cap

€3.0b

7D

1.7%

1Y

n/a

Updated

20 Nov, 2024

Data

Company Financials +

I9SA Stock Overview

A clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. More details

I9SA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Verona Pharma plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verona Pharma
Historical stock prices
Current Share PriceUS$36.40
52 Week HighUS$37.40
52 Week LowUS$10.20
Beta0.42
11 Month Change17.42%
3 Month Change47.97%
1 Year Changen/a
33 Year Change766.67%
5 Year Change905.52%
Change since IPO270.56%

Recent News & Updates

Recent updates

Shareholder Returns

I9SADE PharmaceuticalsDE Market
7D1.7%-7.0%-0.4%
1Yn/a-21.6%7.1%

Return vs Industry: Insufficient data to determine how I9SA performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how I9SA performed against the German Market.

Price Volatility

Is I9SA's price volatile compared to industry and market?
I9SA volatility
I9SA Average Weekly Movement11.7%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: I9SA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: I9SA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200579Dave Zaccardelliwww.veronapharma.com

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.

Verona Pharma plc Fundamentals Summary

How do Verona Pharma's earnings and revenue compare to its market cap?
I9SA fundamental statistics
Market cap€2.96b
Earnings (TTM)-€145.85m
Revenue (TTM)€5.34m

565.3x

P/S Ratio

-20.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
I9SA income statement (TTM)
RevenueUS$5.62m
Cost of RevenueUS$543.00k
Gross ProfitUS$5.08m
Other ExpensesUS$158.80m
Earnings-US$153.72m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin90.35%
Net Profit Margin-2,733.34%
Debt/Equity Ratio92.0%

How did I9SA perform over the long term?

See historical performance and comparison